CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
bimatoprost Formulation A +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01189279
NCT01189279Phase 1Completed
CompareCT.gov

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Allergan·interventional·Posted Aug 26, 2010·Updated Aug 30, 2013

In Brief

A Phase 1 clinical trial evaluating bimatoprost Formulation A, bimatoprost Formulation B, and 1 other intervention for Alopecia and 2 related conditions. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia, Alopecia, Androgenetic, Baldness
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 26, 2010
Enrollment StartOct 1, 2010
Primary CompletionJan 1, 2011
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.8 years ago

Interventions

bimatoprost Formulation Adrug

bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.

bimatoprost Formulation Bdrug

bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.

bimatoprost Formulation Cdrug

bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.